Cytokinetics, Incorporated Securities Lawsuit Investigation

Shamis & Gentile P.A., one of the nation's premier class action law firms specializing in securities fraud cases, is investigating potential claims against Cytokinetics, Inc. (CYTK)

If you purchased or acquired Cytokinetics, Inc. securities between December 27, 2023 and May 6, 2025, you may be eligible to join this class action lawsuit and seek compensation for your losses.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company based in South San Francisco, California focused on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for diseases where muscle performance is compromised or declining.

The company’s lead drug candidate, aficamten, is designed to treat obstructive hypertrophic cardiomyopathy (oHCM), a condition that affects heart muscle function.

The Allegations

The class action lawsuit alleges that Cytokinetics and certain executives made materially false and misleading statements regarding the timeline for FDA approval of its drug aficamten.

The class action complaint claims that the company failed to disclose that its initial New Drug Application (NDA) omitted a required Risk Evaluation and Mitigation Strategy (REMS), even though there had been prior discussions with the FDA about safety and risk mitigation.

This omission became public on May 1, 2025, when Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act (PDUFA) action date for aficamten by three months to review the newly submitted REMS.

The next trading day, May 2, 2025, Cytokinetics’ stock price dropped approximately 13%, erasing hundreds of millions of dollars in market value.

According to the class action complaint, during an earnings call on May 6, 2025, CEO Robert I. Blum admitted that the "Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials."

The class action complaint alleges that investors who purchased shares during the class period paid artificially inflated prices due to the company’s misleading statements and omissions.

The class period for this lawsuit is from December 27, 2023 to May 6, 2025. The complaint, filed on September 17, 2025 in the United States District Court for the Northern District of California, details how investors suffered significant losses when the alleged truth was revealed.

Important Dates

• Class period: December 27, 2023 to May 6, 2025
• Lead plaintiff deadline: November 17, 2025
• Complaint filed: September 17, 2025

Your Rights and Next Steps

If you purchased or acquired Cytokinetics securities during the class period, you have important legal rights.

As an investor who may have suffered losses due to the alleged securities fraud, you can seek to be appointed as a lead plaintiff in the class action. The lead plaintiff acts on behalf of all other class members in directing the litigation.

You are not required to take any action to remain a potential class member, but acting as a lead plaintiff gives you more control over the direction and potential settlement of the case.

Importantly, you do not need to have purchased a minimum number of shares or lost a specific dollar amount to participate. Even if you choose not to be a lead plaintiff, you may still be eligible to receive a portion of any recovery if the lawsuit is successful.

Lawyers are ready to help guide you through the process, answer your questions, and assist you in gathering the necessary documentation. If you believe you were affected, it is important to act before the lead plaintiff deadline on November 17, 2025.

You May Be Entitled to Compensation

If you purchased or acquired Cytokinetics securities between December 27, 2023 and May 6, 2025, you may be entitled to compensation for your losses. Lawyers are ready to help you understand your rights and determine your eligibility.

To take the next step, complete the form below to join the lawsuit and protect your interests as an investor.